R&D Trial complexity is the new normal When operationalised effectively, RBQM can support earlier risk detection and more targeted quality improvement.
News Reviews underway of first drug for rare disease MOGAD Patients with rare autoimmune disease MOGAD could be months away from having a first approved therapy, as the FDA starts a review of Roche's Enspryng.
News FDA starts review of AZ's COPD blockbuster hope The FDA has started a priority review of AstraZeneca's first-in-class IL-33 inhibitor tozorakimab for COPD, setting up a decision in Q1 of 2027.
News FDA makes acting CDER, CBER chiefs permanent Michael Davis becomes the permanent head of CDER, while Karim Mikhail is confirmed as permanent CBER director and the FDA names its first AI leader.
R&D Scientists and algorithms: Finding the right balance in mode... The future of drug development is not scientists versus algorithms. It is scientists and algorithms working together.
Market Access Navigating Europe's AI regulatory labyrinth: A strategic gui... For US drug developers, bringing AI tools across the Atlantic introduces steep regulatory hurdles.
News GSK showcases positive data with lung cancer drugs at WCLC New data at WCLC26 could push GSK's ROS1+ NSCLC drug Jideytro into the first-line setting, while B7-H3-targeted ADC ris-rez extends survival in SCLC.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
